Select Language
Nectin-4
Nectin-4 Overview
| English Name | Nectin-4 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 16 | Target Synonym | PRR4，LNIR，Nectin cell adhesion molecule 4，PVRL4，Ig superfamily receptor LNIR，Poliovirus receptor-related protein 4，NECTIN4，Poliovirus Receptor-Related 4，Nectin-4，Nectin 4，EDSS1 |
| Highest Development Stage | Approved | ||
| English Name | Nectin-4 |
| Target Synonym | PRR4，LNIR，Nectin cell adhesion molecule 4，PVRL4，Ig superfamily receptor LNIR，Poliovirus receptor-related protein 4，NECTIN4，Poliovirus Receptor-Related 4，Nectin-4，Nectin 4，EDSS1 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 16 |
| Highest Development Stage | Approved |
Nectin-4 Product List
- Product Category
Protein (21)Beads (1)Cell (1)Antibody (1)
- Product Status
Launched (24)
- Species
Human (13)Mouse (6)Cynomolgus (4)Rat (1)
- Tag
His Tag (7)His Tag & Avi Tag (7)Fc Tag (4)- (3)Fc Tag & Avi Tag (3)
- Conjugate
Unconjugated (10)Biotin-labeled (10)FITC Labeled (1)- (2)PE Labeled (1)
Add to Cart
Total: 24
- 1
- 2
- 3
Nectin-4 Background
Nectin-4(Nectin cell adhesion molecule 4) is a Nectin and nectin-like family of cell adhesion molecules. It is found in high levels in normal embryonic and fetal tissues, but decreases after adulthood and is limited in distribution in healthy tissues. Nectin-4 is overexpressed in a variety of tumor cells and promotes tumor cell growth and proliferation. Solid tumors with high expression of Nectin-4 include bladder cancer, pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, stomach cancer, esophageal cancer, ovarian cancer and many other cancers. Studies have found that Nectin-4 promotes tumor cell proliferation, differentiation, migration and invasion by activating the PI3K/Akt pathway, and is believed to play an important role in the occurrence and metastasis of cancer. It is based on these research backgrounds that drug research targeting this target has emerged.
Nectin-4 Synonyms
NECTIN4,LNIR, PRR4, PVRL4
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SHR-A2102 | SHR-A2102 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| 9MW-2821 | 9MW-2821; 9-MW2821; 9-MW-2821; 9MW2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Zelenectide pevedotin | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
| SKB-410 | SKB410; SKB-410; MK-3120 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| BA-3361 | BA3361; BA-3361 | Phase 1 Clinical | Bioatla | Neoplasms | Details |
| ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pelvic Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Nectin-4 targeting antibody drug conjugate 2 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| Nectin-4 targeting antibody drug conjugate 1 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| XKDCT-293 | XKDCT-293; XKDCT293 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Breast Neoplasms | Details |
| IPH-4502 | IPH4502; IPH-4502 | Phase 1 Clinical | Innate Pharma SA | Solid tumours | Details |
| LY-4052031 | LY-4052031 | Phase 1 Clinical | Eli Lilly & Company Lilly France | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pelvic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SC-101 | SC-101; SC101 | Phase 1 Clinical | Tianjin Conjustar Biotechnology Co Ltd | Solid tumours | Details |
| ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Solid tumours; Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Uterine Cervical Neoplasms | Details |
| BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Enfortumab vedotin | AGS-22M6E; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22ME; AGS-22C3; ASG-22CE; AGS-M6; AGS-22C3E | Approved | Agensys Inc, Seagen Inc | Padcev, 备思复 | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Hepatocellular | Details |
Product Reviews
O***s2022-07-30
0People LikeWe used this for an important reagent in discovery campaigns. This was a great product! It came sooner than expected, which was awesome because we were able to easily make deadlines! It was also high quality. We didn't have any problems with it, so I am very happy with the quality of service and product. I will definitely buy again. Thank you very much.- 1***82019-10-11 8People LikeI Purchased this antigen for monoclonal antibody generation and antibody screening. The purity has been test by SDS-PAGE. It has a single band and no heterologous protein. It was used for antibody screening, and the screened antibody has a good affinity with the antigen.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland